Fig. 5

COVID-19 associated hypoxia is potentially mediated by HIF-1 and EP/p300, possibly disrupting the vascular bed. Long-COVID data has been intersected with Mild and Severe COVID-19 data sets, each normalized to the healthy control group (meta-analysis was performed with KEGG Mapper and confirmed by iPathwaysGuide software). Venn diagram at the left shows the intersection of the total number of signaling pathways among the clinical groups (iPathwayGuide). A One of the pathways predicted to support vasculo-proliferative disease was HIF-1-signaling pathway. Diagrams represent sequences of the HIF-1 pathways mapped onto KEGG charts and analyzed by iPathwayGuide software. The configuration of this pathway evolved from Mild COVID-19 to Severe COVID-19, having the most prominent representation in Long-COVID. Note: vasculo-proliferative disease is regularly mediated by HIF, which increases both proliferation and angiogenesis. B Table shows the drugs associated with the HIF pathway which can be repurposed for Long-COVID therapeutics (drug Bank output)